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ABSTRACT
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
death worldwide. For advanced HCC, there is still an unmet need for more effective 
therapeutic strategies. HCC is typically associated with hypoxia and the hypoxia-
inducible factor (HIF) regulatory pathway plays an important role in HCC development 
and progression. Therefore, we investigated the therapeutic potential of isoform-
specific HIF-1α and HIF-2α antisense oligonucleotides (ASOs), along with their effect 
on the inflammatory and fibrotic component of the tumor microenvironment (TME), 
in an experimental HCC mouse model. Based on its efficacy and safety, a dosage 
regimen of 20 mg/kg intraperitoneal injection of HIFα ASO twice per week was 
selected for further investigation in a preventive and therapeutic setting in a N,N-
diethylnitrous amide (DEN)-induced HCC mouse model. DEN administration resulted 
in 100% tumor formation and HIFα ASO administration led to effective and selective 
hepatic downregulation of its target genes. HIFα ASO treatment had no effect on 
tumor numbers, but even enhanced the increased hepatic expression of HCC tumor 
markers, α-fetoprotein and glypican-3, compared to scrambled control ASO treatment 
in HCC mice. Especially HIF-1α ASO treatment resulted in an enhanced increase of 
monocytes and monocyte-derived macrophages in the liver and an enhanced hepatic 
upregulation of inflammatory markers. Both HIFα ASOs aggravated liver fibrosis in 
HCC mice compared to scrambled ASO treatment. The observed effects of our dosing 
regimen for HIF-1α and HIF-2α ASO treatment in the DEN-induced HCC mouse model 
discourage the use of HIFα isoforms as targets for the treatment of HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) represents the 
majority of primary liver cancer cases and is currently 
the fourth most common cause of cancer-related death 
worldwide [1–2]. HCC usually occurs in a background 
of chronic liver disease, mainly caused by viral hepatitis, 
chronic alcohol abuse or non-alcoholic fatty liver disease 
(NAFLD) [1, 3]. This environment of repetitive hepatic 
damage and genomic instability contributes to the broad 
array of genetic and epigenetic alterations by which the 
heterogeneous molecular pathogenesis of this malignancy 
is characterized [4]. A frustrating discrepancy exists 
between the stage at which HCC is commonly first 
diagnosed and the stage at which curative treatment 
options are currently available [3]. HCC is an aggressive 
cancer and is often diagnosed at an advanced stage, 
while possible curative interventions, including ablation, 
resection and liver transplantation, are only effective at 
an early disease stage [3, 5]. For advanced HCC, several 
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systemic therapies with minor survival benefits and 
considerable adverse events are available in the form of 
multikinase inhibitors and immune checkpoint inhibitors. 
Currently, two oral tyrosine kinase inhibitors are approved 
as first-line treatment of advanced HCC, namely sorafenib 
and lenvatinib [1, 2]. For second-line treatment, the 
currently approved options are the multitargeted tyrosine 
kinase inhibitors regorafenib and cabozantinib, and the 
human monoclonal vascular endothelial growth factor 
receptor (VEGFR)2-targeting antibody ramucirumab, 
which all yield only limited clinical benefits [2]. In 
addition to these targeted therapies, immune-based 
therapies are, due to their relatively higher response rates, 
emerging as promising treatment options for advanced 
HCC. Currently, the anti-programmed cell death protein 
1 (PD-1) antibodies nivolumab and pembrolizumab 
are the only immune checkpoint inhibitors approved as 
second-line therapy for advanced HCC following failure 
of sorafenib [1, 6]. The clinical benefit of other immune 
checkpoint-targeting therapies, including the cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) inhibitor 
tremelimumab, and the synergistic effect of combination 
therapies of kinase inhibitors, immune checkpoint 
inhibitors and/or locoregional therapies are being 
extensively investigated in clinical trials [6]. However, 
despite the emergence of immunotherapy in the treatment 
landscape of HCC, there is still an unmet need for more 
effective therapeutic strategies [7].
In order to sustain their tumorigenicity and 
proliferative behavior, HCC cells have the ability 
to metabolically adapt to a nutrient-deprived 
microenvironment [8–9]. Indeed, cancer cells are able 
to reprogram their energy metabolism towards aerobic 
glycolysis, a phenomenon called the Warburg effect 
[10–12]. Due to the oxygen-consuming hypermetabolism 
of the rapidly proliferating tumor cells, HCC is typically 
associated with hypoxia in the intratumoral regions [13–
14]. This hypoxic microenvironment promotes tumor 
aggressiveness and therapeutic resistance primarily through 
activation of the hypoxia-inducible factor (HIF) regulatory 
pathway [14, 15]. This hypoxia-responsive pathway 
consists of α-subunits (HIFα, including HIF-1α, HIF-2α/
EPAS1 and HIF-3α) and β-subunits (HIFβ, including HIF-
1β/ARNT1, ARNT2 and ARNT3) [15]. Under normoxia, 
the HIFα subunit is hydroxylated at two proline residues 
by prolyl hydroxylase domain-containing protein (PHD), 
and subsequently ubiquitinated by von Hippel-Lindau 
tumor suppressor protein (pVHL) and degraded by the 
26S proteasome. Additionally, factor inhibiting HIF (FIH) 
mediates asparaginyl hydroxylation of HIFα, thereby 
inhibiting its interaction with transcriptional coactivators 
CREB-binding protein (CBP) and p300. Both PHD and 
FIH are oxygen-dependent enzymes, which implies that 
they are inactive under hypoxic conditions. Therefore, 
in hypoxia-associated cancers, including HCC, the HIFα 
subunit is stabilized, leading to its nuclear translocation. 
After dimerization with the constitutively expressed HIFβ 
subunit, and interaction with transcriptional activators CBP 
and p300, the resultant heterodimer acts as a transcription 
factor, upregulating the expression of a large number 
of hypoxia-responsive target genes by binding to the 
hypoxia response element (HRE) in their promoter region 
[13, 15]. These genetic targets comprise multiple cancer 
hallmark-implicated genes, including genes involved in 1) 
angiogenesis, such as vascular endothelial growth factor 
(VEGF), erythropoietin (EPO) and platelet-derived growth 
factor (PDGF); 2) metabolism, such as glucose transporter 
1 (GLUT1), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and phosphoglycerate kinase 1 (PGK1); 3) 
proliferation, such as insulin-like growth factor 2 (IGF-2) 
and transforming growth factor (TGF)-α; and 4) invasion 
and metastasis, such as lysyl oxidase (LOX) and several 
matrix metalloproteinases (MMPs). Thus, in HCC and 
other hypoxia-associated tumors, the HIF pathway has a 
key role in shaping the tumor microenvironment (TME) 
[13, 15–18]. Consequently, targeting hypoxia and, more 
specifically, the HIF pathway appears to be a plausible 
therapeutic strategy for the treatment of HCC [13, 15]. To 
date, in addition to downstream HIF signaling pathway-
targeting strategies, including the approved VEGFR-
targeting drugs sorafenib, lenvatinib, regorafenib, 
cabozantinib and ramucirumab, an array of HIF-targeting 
compounds have been identified and investigated in 
preclinical studies and clinical trials [13, 15, 19–20]. A 
substantial part of these HIF-targeting compounds are 
inhibitors of HIF messenger ribonucleic acid (mRNA) 
or protein expression. These include compounds that 1) 
target the phosphoinositide 3-kinase/protein kinase B/
mammalian target of rapamycin (PI3K/AKT/mTOR) 
pathway (regulates HIFα mRNA translation), 2) inhibit 
topoisomerase 1 (regulates HIFα mRNA translation), 3) 
directly target HIF-1α mRNA expression (synthetic HIF-
1α antisense oligonucleotides), 4) disrupt microtubules 
(orchestrate HIFα mRNA translation), 5) inhibit heat 
shock protein 90 (Hsp90), which induces proteasomal 
degradation of HIFα, 6) inhibit histone deacetylase 
(HDAC), which inhibits nuclear translocation of HIFα, 
or 7) promote iron-regulatory protein 1/iron-responsive 
element (IRP1/IRE) interaction (HIF-2α translational 
inhibitors). Other HIF pathway-targeting compounds 
may act through inhibition of HIFα/HIFβ dimerization, 
by inhibiting binding of HIF to the HRE of its target 
genes, or by inhibiting transcriptional activity of HIF 
(e.g., by inhibiting interaction of HIF with transcriptional 
coactivator p300) [13, 15, 19]. Despite this already 
significant amount of HIF pathway-targeting options, only 
a few of them have moved beyond the preclinical stage 
for therapeutic application in HCC [13, 15]. One of the 
most important limitations of these compounds is their 
lack of specificity towards a certain isoform of HIF, as 
the different isoforms, in addition to a substantial overlap, 
also have substantial differences in their array of target 
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genes, and this may lead to opposing effects on the TME. 
Therefore, due to the relevance of the HIF pathway in 
several aspects of HCC development and progression, it 
is of great importance to further explore the therapeutic 
potential of isoform-specific HIF pathway-targeting 
strategies and their effect on the TME [13, 15, 19]. Here, 
we investigated the therapeutic potential of isoform-
specific HIF-1α and HIF-2α antisense oligonucleotides 
(ASOs; provided by Ionis Pharmaceuticals), along with 
their effect on several TME-associated features, including 
inflammation and fibrosis, in a N,N-diethylnitrous amide 
(DEN)-induced HCC mouse model.
RESULTS
Pilot study for selection of optimal dosage 
regimen
In order to define the optimal dosage regimen of 
the isoform-specific HIF-1α and HIF-2α ASOs used in 
further experiments, healthy mice were intraperitoneally 
injected with 10, 20 or 100 mg/kg HIF-1α or HIF-2α ASO, 
or 20 mg/kg scrambled ASO, twice per week for 2 weeks. 
Neither of the dosage regimens influenced the body 
weight of the mice. However, compared to scrambled ASO 
treatment, statistically significant hepatic enlargement was 
observed for both 100 mg/kg HIF-1α and HIF-2α ASO, 
while this was not observed for lower dosage regimens of 
both isoform-specific HIFα ASOs (Figure 1A). 
Efficacy and selectivity of the HIFα ASOs was 
evaluated by comparing hepatic mRNA expression of all 
three HIFα isoforms in response to the different dosage 
regimens of HIF-1α and HIF-2α ASO, and scrambled 
control treatment. Both HIFα ASOs led to significant 
downregulation of mRNA expression of their respective 
target gene in a dose-dependent manner, compared to 
scrambled ASO treatment. The expression of HIF-1α was 
unaffected by HIF-2α ASO treatment, whereas HIF-1α 
ASO treatment showed a significant but neglectable effect 
(less than 2-fold change) on HIF-2α expression. Neither of 
the isoform-specific HIFα ASO treatments affected mRNA 
expression of the HIF-3α isoform (Figure 1B). 
Potential liver injury of the different dosage 
regimens was assessed via hepatic mRNA expression 
of several inflammation-associated markers. Compared 
to scrambled ASO treatment, expression of the pro-
inflammatory cytokine tumor necrosis factor (TNF)α, 
vascular cell adhesion molecule (VCAM)-1 (mediates 
adhesion of several immune cells to vascular endothelium), 
C-C motif chemokine ligand (CCL)2 (mediates monocyte 
Figure 1: Efficacy and selectivity of different dosage regimens of HIF-1α and HIF-2α ASO. Mice were intraperitoneally 
injected with 10, 20 or 100 mg/kg HIF-1α or HIF-2α ASO, or 20 mg/kg scrambled ASO, twice per week for 2 weeks. (A) Body weight and 
relative liver weight (expressed as % to body weight) following treatment period. The upper and lower dashed lines represent mean ± SD 
of the scrambled ASO data. Mean ± SD of other data are represented as bars (n = 4 per treatment group). (B) Hepatic mRNA expression of 
the HIFα isoforms following treatment period. The upper and lower dashed lines represent mean ± SD of the log2-transformed 20 mg/kg 
scrambled ASO data. Log2-transformed mean ± SD of other data, relative to the log2-transformed mean of the 20 mg/kg scrambled ASO 
treatment group, are represented as bars (n = 4 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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chemotaxis) and C-X-C motif chemokine ligand (CXCL)2 
(involved in immune cell chemotaxis) was significantly 
upregulated following 20 mg/kg and 100 mg/kg HIF-1α 
and HIF-2α ASO treatment in a dose-dependent manner, 
whereas for the multifunctional cytokine TGF-β and C-C 
motif chemokine receptor (CCR)2 (mediates monocyte 
chemotaxis), hepatic expression was only increased 
following 100 mg/kg HIFα ASO treatment (Figure 2).
Based on the efficacy, as well as potential 
hepatotoxicity observed for the different treatment 
regimens, 20 mg/kg was selected as the optimal dose for 
further experiments.
Selective and effective hepatic downregulation of 
target genes following HIFα ASO treatment in 
HCC mice
Efficacy and selectivity of isoform-specific HIFα 
ASO treatment was evaluated in the preventive and 
therapeutic setting in DEN-induced HCC mice. HIF-
1α ASO effectively downregulated HIF-1α mRNA 
expression in both settings compared to healthy control 
mice and compared to other ASO treatment groups. 
HIF-1α expression was also slightly decreased after 15 
weeks of scrambled and HIF-2α ASO administration, 
whereas therapeutic treatment of these ASOs resulted in 
minor upregulation of hepatic HIF-1α expression. HIF-2α 
ASO administration also selectively downregulated the 
expression of its target gene compared to all other groups. 
In addition, therapeutic HIF-1α ASO treatment resulted 
in minor upregulation of HIF-2α expression, compared to 
healthy control mice. In the therapeutic setting, all HCC 
mice showed increased expression of HIF-3α compared 
to healthy control mice without differences between 
treatment groups (Figure 3). 
Effect of HIFα ASO treatment on 
hepatocarcinogenesis
The effect of isoform-specific HIFα ASOs on 
the development of HCC (preventive setting) and their 
potential as therapeutic strategy for HCC (therapeutic 
setting) were assessed in the established DEN-induced 
HCC mouse model, which is known to be characterized 
by hypoxia and induction of the HIF pathway [21–22]. 
Regardless of the ASO treatment, all DEN-injected mice 
showed lower body weight at the end of the experiment 
compared to healthy control mice, however without 
significance. Only preventive HIF-1α ASO administration 
resulted in significant hepatic enlargement in HCC mice 
compared to healthy control mice and other treatment 
groups, whereas in the therapeutic setting, both HIF-
1α and HIF-2α ASO treatment resulted in significant 
hepatomegaly (Figure 4A).
Figure 2: Effect of different dosage regimens of HIF-1α and HIF-2α ASO on hepatic expression of inflammatory 
markers. Mice were intraperitoneally injected with 10, 20 or 100 mg/kg HIF-1α or HIF-2α ASO, or 20 mg/kg scrambled ASO, twice per 
week for 2 weeks. Hepatic mRNA expression of the inflammatory markers TNFα, TGF-β, VCAM-1, CCR2, CCL2 and CXCL2 following 
treatment period is shown. The upper and lower dashed lines represent mean ± SD of the log2-transformed 20 mg/kg scrambled ASO data. 
Log2-transformed mean ± SD of other data, relative to the log2-transformed mean of the 20 mg/kg scrambled ASO treatment group, are 
represented as bars (n = 4 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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To investigate the effect of isoform-specific HIF-
1α and HIF-2α ASO on HCC tumorigenesis, the number 
of macroscopically visible hepatic tumoral lesions in the 
different treatment groups was evaluated. DEN treatment 
led to a rough nodular hepatic surface with multiple 
macroscopic lesions in all treatment groups. However, 
no significant effect of HIFα ASO treatment could be 
observed. The overall number of tumoral lesions was 
higher in HCC mice euthanized 28 weeks following first 
DEN injection (therapeutic setting), compared to mice that 
were euthanized three weeks earlier (preventive setting) 
(Figure 4B). 
The effect of isoform-specific HIFα ASO treatment 
on HCC tumorigenesis was further investigated via 
assessment of hepatic mRNA expression of the HCC 
tumor markers α-fetoprotein (AFP) and glypican-3 
(GPC3). None of the HCC mice that were euthanized 25 
weeks following first DEN injection showed significantly 
increased expression of HCC markers compared to healthy 
control mice, whereas all mice euthanized 3 weeks later 
did. With the exception of GPC3 in 15 weeks HIF-1α ASO 
treated mice, HCC markers were upregulated in HIFα 
ASO-treated HCC mice compared to scrambled ASO-
treated HCC mice, both in the preventive and therapeutic 
setting (Figure 4C).
HIF-1α ASO treatment induces a pro-
inflammatory TME in DEN-induced HCC mice
The effect of HIF-1α and HIF-2α ASO treatment 
on the inflammatory component of the TME in the DEN-
induced HCC mouse model was first assessed via flow 
cytometric analysis of the hepatic macrophage pool. 
As previously published by our group, the percentage 
and number of CD11b+Ly6C-F4/80+Tim4+ Kupffer 
cells (KCs) was significantly decreased in HCC 
mice, independent from treatment [23]. As expected, 
DEN-induced HCC resulted in a marked increase of 
CD11b+Ly6C+Ly6G- monocytes and CD11b+Ly6C-
F4/80+Tim4- monocyte-derived macrophages (MoMfs) 
in the liver, which was most pronounced in mice treated 
with HIF-1α ASO (Figure 5).
Figure 3: Efficacy and selectivity of preventive and therapeutic HIF-1α and HIF-2α ASO treatment in DEN-induced 
HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly intraperitoneal 
0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or 
scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled ASO for 
the same duration of the experiment. Hepatic mRNA expression of the HIFα isoforms following preventive and therapeutic 
treatment is shown. The upper and lower dashed lines represent log2-transformed mean ± SD of the control mice. Bars 
represent log2-transformed mean ± SD of different treatment groups of DEN-treated mice, relative to the log2-transformed 
mean of the control mice (n = 7–9 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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The effect of isoform-specific HIFα ASO treatment 
on inflammation was further assessed via hepatic 
expression of several inflammatory markers, both at 
mRNA and protein level. DEN-induced HCC resulted in 
significant upregulation of the mRNA levels of the pro-
inflammatory markers TNFα, CCR2, CCL2 and VCAM-
1 (the latter two only in respectively the preventive and 
therapeutic group), and, in most settings, this was most 
pronounced in mice treated with HIF-1α ASO. In addition, 
only HIF-1α ASO-treated mice showed significantly 
increased expression of the pro-inflammatory cytokine 
interleukin (IL)-6 and inducible nitric oxide synthase 
(iNOS) (Figure 6). 
While we did not observe increased protein levels 
of TNFα, IL-6 and interferon (IFN)-γ, nor effect of ASO 
treatment on these protein levels, in mice with HCC, 
CCL2 and CCL5 protein levels, responsible for leukocyte 
recruitment, were significantly increased in HCC mice and 
this was most pronounced for HIF-1α ASO-treated mice in 
the preventive setting (Figure 7).
HIFα ASO treatment aggravates fibrosis in 
DEN-induced HCC mice
In the vast majority of the cases, HCC develops on a 
fibrotic background. As hypoxia, and more specifically the 
HIF pathway, plays an important role in HCC-associated 
fibrogenesis, we investigated the effect of isoform-
specific HIF-1α and HIF-2α ASO treatment on fibrosis 
in the DEN-induced HCC mouse model [24, 25]. DEN-
induced hepatocarcinogenesis only resulted in minor 
fibrosis, with Metavir fibrosis stages ranging from F1 
to F2, as previously published [26]. Remarkably, HIFα 
ASO treatment aggravated fibrosis in the livers of DEN-
treated mice, both in the preventive and therapeutic setting 
(Figure 8).
The effect of isoform-specific HIFα ASO treatment 
on liver fibrosis was further assessed via hepatic mRNA 
expression of several fibrotic markers. The expression of 
α-smooth muscle actin (α-SMA), which is a marker for 
the formation of extracellular matrix (ECM)-producing 
myofibroblasts, confirmed our histological analysis 
with significant upregulation in HIFα ASO-treated HCC 
mice. Furthermore, several matrix metalloproteinases 
(MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs) involved in fibrogenesis and HCC progression 
were upregulated in the livers of HCC mice, which was 
again most pronounced following HIFα ASO treatment 
(Figure 9).
DISCUSSION
Due to the worldwide increase of the incidence 
of some of its major etiological risk factors, including 
chronic alcohol abuse and NAFLD, HCC is a growing 
health problem [1, 27–28]. It is often only diagnosed at 
Figure 4: Effect of preventive and therapeutic HIF-1α and HIF-2α ASO treatment on hepatocarcinogenesis in 
DEN-induced HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly 
intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or 
scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled ASO for the same duration 
of the experiment. (A) Body weight and relative liver weight (expressed as % to body weight) following preventive and therapeutic 
treatment. The upper and lower dashed lines represent mean ± SD of the control mice. Bars represent mean ± SD of different treatment 
groups of DEN-treated mice (n = 6–8 per treatment group). (B) Upper part: Hepatic tissue of healthy control mice and DEN-treated mice. 
Lower part: Total number of macroscopic hepatic lesions following preventive and therapeutic treatment. Data are represented as individual 
values with the median (n = 6–8 per treatment group). (C) Hepatic mRNA expression of the HCC tumor markers AFP and GPC3 following 
preventive and therapeutic treatment. The upper and lower dashed lines represent log2-transformed mean ± SD of the control mice. Bars 
represent log2-transformed mean ± SD of different treatment groups of DEN-treated mice, relative to the log2-transformed mean of the 
control mice (n = 7–9 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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an advanced stage, at which current treatment options are 
limited and unsatisfactory [3, 5, 29]. Therefore, promising 
novel therapeutic targets need to be explored [7]. As the 
HIF pathway regulates multiple cancer hallmarks and 
consequently has a key role in shaping the HCC TME, 
targeting this hypoxic response pathway represents an 
attractive strategy for HCC treatment. To date, only a small 
portion of HIF pathway-targeting compounds has moved 
beyond the preclinical stage. A common and important 
limitation is the lack of specificity towards a certain HIF 
isoform [13, 15]. Therefore, this study aimed to explore 
the therapeutic potential of isoform-specific HIF pathway 
targeting by means of selective HIF-1α and HIF-2α 
ASOs. In addition to their effect on HCC development 
and progression, the influence on the inflammatory and 
fibrotic component of the TME was assessed. In our 
study, HIFα ASO treatment selectively downregulated 
its target gene, but did not exert a beneficial effect on 
hepatocarcinogenesis, induced a pro-inflammatory TME 
and aggravated fibrosis in the liver of DEN-induced HCC 
mice.
Three HIFα isoforms (HIF-1α, HIF-2α and HIF-3α) 
have been described so far [30]. Increased expression of 
both HIF-1α and HIF-2α has been observed in several 
chronic liver diseases, including alcoholic liver disease 
(ALD), NAFLD and HCC [31]. Especially HIF-1α 
expression has been shown to be positively correlated with 
poor prognosis, tumor grade, metastasis and lower overall 
survival rate [15, 31–32]. The observed upregulation of 
HIF-1α in HCC mice euthanized 28 weeks following first 
DEN injection (therapeutic setting), compared to mice that 
were euthanized three weeks earlier (preventive setting), 
along with the increased number of macroscopic tumoral 
lesions, indeed indicates that HIF-1α expression increases 
in advanced HCC. The contribution of HIF-2α in HCC 
pathogenesis is less clear, as both tumor promoting and 
Figure 5: Effect of therapeutic HIF-1α and HIF-2α ASO treatment on hepatic macrophage pool in DEN-induced 
HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly intraperitoneal 0.9% 
NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or scrambled ASO twice per 
week, in a therapeutic setting. Control mice received scrambled ASO for the same duration of the experiment. Upper part: Percentage 
of CD11b+Ly6C-F4/80+Tim4+ Kupffer cells, CD11b+Ly6C+F4/80+Tim4- monocytes and CD11b+Ly6C-F4/80+Tim4- monocyte-derived 
macrophages in live CD45+ single cell gate following treatment, measured by flow cytometry. The upper and lower dashed lines represent 
mean ± SD of the control mice. Bars represent mean ± SD of different treatment groups of DEN-treated mice (n = 6–7 per treatment 
group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Lower part: Number of live CD45+CD11b+Ly6C-F4/80+Tim4+ Kupffer cells, 
CD45+CD11b+Ly6C+F4/80+Tim4- monocytes and CD45+CD11b+Ly6C-F4/80+Tim4- monocyte-derived macrophages per gram liver tissue 
following treatment, measured by flow cytometry. The upper and lower dashed lines represent mean ± SD of the control mice. Bars 
represent mean ± SD of different treatment groups of DEN-treated mice (n = 6–7 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001.
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tumor suppressing results have been published [31, 32]. 
Observed discrepancies in the involvement of HIF-1α 
and HIF-2α in HCC development and progression can 
be explained by the fact that, in addition to a substantial 
overlap of target genes, they each also regulate a distinct 
set of genes [30, 32]. 
A dose-finding study was set up in order to define 
the optimal dosage regimen of the isoform-specific 
HIFα ASOs. Both HIFα ASOs selectively downregulate 
mRNA expression of their respective target gene. 
Only for HIF-2α ASO treatment, dose increase above 
20 mg/kg resulted in more effective HIF-2α mRNA 
downregulation. Furthermore, for both HIFα ASOs, 
the 100 mg/kg dosage regimen resulted in significant 
hepatomegaly and upregulation of the mRNA expression 
of several inflammation-associated markers, including 
TNFα, VCAM-1, CCR2, CCL2 and CXCL2, compared 
to lower dosage regimens, indicating dose-dependent 
hepatotoxicity. Consequently, based on its efficacy and 
safety, we opted for a dosage regimen of 20 mg/kg twice 
per week, for both HIF-1α and HIF-2α ASO, in subsequent 
experiments. 
Figure 6: Effect of preventive and therapeutic HIF-1α and HIF-2α ASO treatment on hepatic mRNA expression of 
inflammatory markers in DEN-induced HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. 
Control mice received weekly intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-
1α ASO, HIF-2α ASO or scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled 
ASO for the same duration of the experiment. Hepatic mRNA expression of several inflammatory markers following preventive and 
therapeutic treatment is shown. The upper and lower dashed lines represent log2-transformed mean ± SD of the control mice. Bars represent 
log2-transformed mean ± SD of different treatment groups of DEN-treated mice, relative to the log2-transformed mean of the control mice 
(n = 7–9 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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In order to investigate the effect of isoform-
specific HIFα inhibition on HCC tumorigenesis, a 
DEN-induced HCC mouse model was employed. This 
experimental HCC mouse model was selected due to its 
physiologically relevant TME and immune modifications 
related to HCC development and progression, as long-
term repetitive DEN administration induces both chronic 
liver inflammation and mild fibrosis [33]. DEN injections 
resulted in formation of macroscopic hepatic lesions in 
100% of the cases. Tumor formation was associated with 
upregulated mRNA expression of the established HCC 
tumor markers AFP and GPC3 [34–35]. Flow cytometric 
analysis of the hepatic macrophage pool confirmed KC 
depletion, simultaneous Ly6C+ monocyte infiltration and 
increased MoMfs [23, 36]. Hepatic infiltration of immune 
cells and establishment of a pro-inflammatory TME was 
Figure 7: Effect of preventive and therapeutic HIF-1α and HIF-2α ASO treatment on hepatic protein expression of 
inflammatory markers in DEN-induced HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. 
Control mice received weekly intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-
1α ASO, HIF-2α ASO or scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled 
ASO for the same duration of the experiment. Hepatic protein expression of several inflammatory markers following preventive and 
therapeutic treatment is shown. The upper and lower dashed lines represent mean ± SD of the control mice. Bars represent mean ± SD of 
different treatment groups of DEN-treated mice (n = 7–9 per treatment group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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further confirmed via upregulated expression of several 
inflammatory markers, including TNFα, CCR2, CCL2, 
CCL5 and VCAM-1, at either mRNA or protein level 
[37–40]. Portal fibrosis without septa (Metavir fibrosis 
stage F1) was observed in the peritumoral hepatic tissue, 
in both treatment settings. Furthermore, the observed 
upregulation of the hepatic mRNA expression of MMP-
2, MMP-14 and TIMP-1 is in line with the establishment 
of a fibrotic TME following chronic DEN administration 
[41–43]. Thus, as the DEN-induced HCC mouse model 
mimics the human HCC-associated TME in several 
aspects, it is a suitable experimental HCC model for 
investigation of the therapeutic potential of our isoform-
specific HIFα ASOs. 
As macroscopic HCC lesions are only observed 
following approximately 20 weeks of weekly 35 mg/
kg DEN injections, initiation of HIFα ASO treatment 
10 weeks following the first DEN injection enables 
investigation of its effect on HCC initiation and 
development (preventive setting) [26, 44]. Starting 
HIFα ASO treatment 20 weeks following first DEN 
administration allows to assess its effect on the 
progression of HCC (therapeutic setting). As it was the 
case in the dose-finding study, in both treatment settings, 
isoform-specific HIF-1α and HIF-2α ASO effectively 
and selectively downregulated hepatic mRNA expression 
of their target gene. Biometric data however gave some 
indications of worse general and hepatic condition of the 
HIFα ASO-treated mice, as in some treatment groups, 
relative to the scrambled ASO treatment group, additional 
weight loss and/or hepatomegaly was observed.
Regarding the effect of specific HIF-1α and HIF-2α 
inhibition on HCC tumorigenesis, preventive treatment 
did not inhibit or slow down tumor development in our 
HCC mouse model, as macroscopic lesions were present 
in 100% of the ASO-treated mice and furthermore, 
were more numerous compared to the scrambled ASO 
treatment group. Moreover, following both preventive 
and therapeutic HIF-1α and HIF-2α ASO treatment, 
upregulated hepatic mRNA expression of AFP and/
or GPC3 was observed, as compared to scrambled 
ASO treatment. This finding is supported by previous 
research which showed that HIF-1α overexpression 
downregulates transcriptional activity of the AFP and 
GPC3 genes in HCC cells, through competition with the 
oncogenic transcription factor c-Myc [45–46]. Thus, in 
this case, experimental HIF-1α inhibition might result in 
c-Myc-dependent upregulation of AFP and GPC3 mRNA 
expression. In addition, HIF-2α-mediated inhibition 
of tumor growth in HCC has also been previously 
described [47]. Consequently, the observed absence of 
beneficial effect of isoform-specific HIFα inhibition on 
the development of macroscopic HCC lesions, together 
with upregulated hepatic mRNA expression of HCC 
Figure 8: Effect of preventive and therapeutic HIF-1α and HIF-2α ASO treatment on liver fibrosis in DEN-induced 
HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly intraperitoneal 0.9% 
NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or scrambled ASO twice per 
week, in either a preventive or a therapeutic setting. Control mice received scrambled ASO for the same duration of the experiment. Upper 
part: Representative histological images of Sirius Red-stained liver sections with Metavir fibrosis stage F0 (no fibrosis), F1 (portal fibrosis 
without septa) and F2 (portal fibrosis with few septa). Magnification 200×. Lower part: Degree of hepatic fibrosis following preventive and 
therapeutic treatment, assessed through histological analysis of Sirius Red-stained liver sections using the Metavir scoring system. Data are 
represented as individual values with the median (n = 7–9 per HCC treatment group).
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tumor markers, discourage the use of HIF-1α and HIF-2α 
as targets for the treatment of HCC.
Despite the negative effects of isoform-specific 
HIFα ASO treatment on HCC tumorigenesis in the DEN-
induced HCC mouse model, it is of great importance to 
create a better understanding of the distinct influences 
the different HIFα isoforms exert on the HCC-associated 
TME. As chronic inflammation and fibrosis are two 
major features of human HCC, and are shown to play an 
essential role in its development and progression, we also 
investigated the effect of isoform-specific HIFα inhibition 
on both the inflammatory and fibrotic component of the 
TME associated with experimental DEN-induced HCC 
[48, 49]. 
Both HIF-1α and HIF-2α have been demonstrated 
to play essential roles in monocyte recruitment and 
macrophage differentiation in many cancers, including 
HCC [37, 50–52]. However, in our HCC model, isoform-
specific HIFα inhibition resulted in increased Ly6C+ 
monocyte infiltration and/or MoMf differentiation. The 
Figure 9: Effect of preventive and therapeutic HIF-1α and HIF-2α ASO treatment on fibrotic markers in the liver of 
DEN-induced HCC mice. HCC was induced by weekly intraperitoneal DEN injection for 25 weeks. Control mice received weekly 
intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or 
scrambled ASO twice per week, in either a preventive or a therapeutic setting. Control mice received scrambled ASO for the same duration 
of the experiment. Hepatic mRNA expression of fibrotic markers following preventive and therapeutic treatment is shown. The upper and 
lower dashed lines represent log2-transformed mean ± SD of the control mice. Bars represent log2-transformed mean ± SD of different 
treatment groups of DEN-treated mice, relative to the log2-transformed mean of the control mice (n = 7–9 per treatment group). *p < 0.05, 
**p < 0.01, ***p < 0.001 and ****p < 0.0001.
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pro-inflammatory effect of HIFα inhibition on the HCC 
TME was further demonstrated by upregulated hepatic 
mRNA and/or protein expression of several inflammation-
related markers, namely the pro-inflammatory cytokines 
TNFα, IL-6 and IFN-γ, the M1-like macrophage marker 
iNOS, and the immune cell infiltration-related markers 
CCL2, CCL5 and VCAM-1.
Both HIF-1α and HIF-2α transcriptional activity 
have also been demonstrated to directly or indirectly 
contribute to fibrogenesis [24, 31, 53, 54]. However, 
in both treatment settings, isoform-specific HIFα 
inhibition resulted in an increased extent of fibrosis in the 
peritumoral hepatic tissue. This pro-fibrotic effect of HIFα 
inhibition on the HCC TME was further demonstrated by 
upregulated hepatic mRNA expression of several fibrotic 
markers, namely α-SMA, MMP-2, MMP-10, MMP-14, 
MMP-16 and/or TIMP-1.
The observed negative effects of both isoform-
specific HIF-1α and HIF-2α ASO treatment on HCC 
tumorigenesis in our DEN-induced HCC mouse model, 
discourage the use of HIF-1α and HIF-2α as targets for the 
treatment of HCC. Furthermore, the pro-inflammatory and 
pro-fibrotic effects on the HCC TME also raise questions 
about the use of HIFα ASOs, in the dosing regimen 
we have investigated, in other cancers, with respect to 
potential hepatotoxicity. Further preclinical studies testing 
dosing strategies might indicate if lower doses of isoform-
specific HIFα ASOs can be used without potential harm 
and might be of interest as anti-cancer therapy.
MATERIALS AND METHODS
Animals
Male wild type 129/Sv mice were purchased from 
Janvier Labs (Le Genest-Saint-Isle, France) at 4 weeks of age 
and housed in open cages in a temperature-controlled room 
at 20°C with a 12 hour light/dark cycle at the laboratory 
animal facility of the Faculty of Medicine and Health 
Sciences (Ghent University, Ghent, Belgium). Mice were 
given ad libitum access to food (mouse maintenance chow; 
Carfil Quality – Labofood, Oud-Turnhout, Belgium) and 
water. Mice were acclimatized under controlled conditions 
for one week prior to the experiments. All mice received 
care in accordance with the “Guide for the Care and Use of 
Laboratory Animals” and the Belgian national guidelines for 
animal protection. HCC was induced at the age of 5 weeks 
via weekly intraperitoneal injections of 35 mg/kg DEN 
(Sigma-Aldrich, Machelen, Belgium), dissolved in 0.9% 
sodium chloride (NaCl; B. Braun, Machelen, Belgium) for 
25 weeks. Control mice received weekly intraperitoneal 
injections of 0.9% NaCl. Mice were monitored for weight 
loss and other external signs of disease or discomfort. 
This study was approved by the Ethical Committee of 
Experimental Animals at the Faculty of Medicine and Health 
Sciences of Ghent University (ECD 18/125).
Dose-finding study
In order to define the optimal dosage regimen of 
the isoform-specific ASOs used in our preventive and 
therapeutic studies, 8-week-old male wild type 129/Sv 
mice were intraperitoneally injected twice per week for 2 
weeks with 10, 20 or 100 mg/kg HIF-1α ASO, 10, 20 or 
100 mg/kg HIF-2α ASO, or 20 mg/kg scrambled ASO (all 
provided by Ionis Pharmaceuticals, Carlsbad, California, 
USA), dissolved in phosphate-buffered saline (PBS; 
Gibco, Thermo Fisher Scientific, Merelbeke, Belgium). 
Afterwards, mice were sacrificed, the liver was isolated 
(see "Tissue sampling") and expression of the different 
HIFα isoforms and several inflammatory markers was 
analyzed via quantitative reverse transcription-polymerase 
chain reaction (RT-qPCR).
Preventive and therapeutic treatment
DEN-treated mice were intraperitoneally injected 
twice per week with 20 mg/kg HIF-1α ASO, HIF-2α ASO 
or scrambled ASO, dissolved in PBS, in either a preventive 
or therapeutic setting. In the preventive setting, ASO 
injections started 10 weeks after the first DEN injection 
(at 15 weeks of age) and persisted for a period of 15 
weeks. In the therapeutic setting, ASO injections started 
20 weeks after the first DEN injection (at 25 weeks of age) 
and persisted 8 weeks. These treatment regimens are based 
on previous publications reporting HCC development by 
weekly DEN injections [26, 44]. Control mice received 
intraperitoneal injections of scrambled ASO twice per 
week. Following treatment, mice were sacrificed and the 
liver was divided for further analyses (Figure 10).
Tissue sampling
Mice were anesthetized via intraperitoneal 
injection of ketamine (60 mg/kg; Dechra Veterinary 
Products, Lille, Belgium) and xylazine (6 mg/kg; Kela, 
Sint-Niklaas, Belgium), and euthanized by cervical 
dislocation. Two pieces of the liver were isolated; one 
was fixed in 4% phosphate-buffered formaldehyde 
solution (Klinipath, Olen, Belgium) for histological 
analysis, and one was incubated in RNAlater (Ambion, 
Thermo Fisher Scientific), snap frozen in liquid nitrogen 
and stored at –80°C until further processing for RT-
qPCR. In mice belonging to the therapeutic treatment 
groups, the remaining liver was perfused with PBS, 
isolated, weighed, chopped into small pieces, further 
dissociated using gentleMACS Dissociator (Miltenyi 
Biotec, Leiden, The Netherlands), and incubated for 20 
minutes in 1 mg/mL Collagenase A (Sigma-Aldrich) 
and 300 μg/mL DNase I (Roche Diagnostics, Machelen, 
Belgium), dissolved in 3 mL Roswell Park Memorial 
Institute medium (RPMI; Gibco), in a shaking heated 
bath (37°C). Obtained cell suspensions were filtered, 
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red blood cells (RBCs) were removed by means of RBC 
Lysis Buffer (composed of 155 mM NH4Cl, 12 mM 
NaHCO3 and 0.1 mM EDTA) and cells were stained 
with appropriate antibodies for flow cytometry. During 
sacrification, mice were weighed, whole-liver weights 
were recorded, and the number of hepatic lesions was 
macroscopically evaluated. Large tumoral lesions were 
removed from the pieces of liver used for downstream 
analysis.
Flow cytometry
Cells were prestained with a 1:100 dilution of 
Zombie Aqua (Fixable Viability Dye; BioLegend, 
London, UK) for 20 minutes at 4°C in the dark. After 10 
minutes, an equal volume of a 1:100 dilution of TruStain 
FcX PLUS (anti-mouse CD16/32 antibody) and True-
Stain Monocyte Blocker (BioLegend) was added. After 
a washing step, cells were stained with CD3e-PerCP-
Cy5.5, CD19-PerCP-Cy5.5 (eBioscience, Thermo Fisher 
Scientific), NK1.1-PerCP-Cy5.5, CD103-PerCP-Cy5.5, 
F4/80-FITC, Ly6G-BV785, Ly6C-BV650 (BioLegend), 
SiglecF-PerCP-Cy5.5, CD45-APC-Cy7, CD11b-PE-
Cy7 and Tim4-PE (BD Biosciences, Erembodegem, 
Belgium) for 20 minutes at 4°C in the dark. Cells were 
analyzed with a BD FACSAria Fusion flow cytometer 
(BD Biosciences) and FlowJo software (FlowJo LLC, 
BD Biosciences), and gated first as live CD45+ single 
cells. Subsequently, CD3e+, CD19+, NK1.1+, CD103+ and 
SiglecF+ cells were eliminated, and CD11b+Ly6C+Ly6G- 
monocytes, CD11b+Ly6C-F4/80+Tim4+ Kupffer cells 
(KCs) and CD11b+Ly6C-F4/80+Tim4- monocyte-derived 
macrophages (MoMfs) were gated.
RT-qPCR
RNA was extracted from 20 mg of frozen liver 
tissue preserved in RNAlater, according to the instruction 
manual of the Aurum Total RNA Mini Kit (Bio-Rad 
Laboratories, Temse, Belgium), and measured for 
purity and quantity by spectrophotometry (NanoDrop; 
Thermo Fisher Scientific). cDNA was obtained from 
one microgram of RNA by reverse transcription using 
the SensiFAST cDNA Synthesis Kit (Bioline, London, 
UK) according to the manufacturer’s guidelines. Diluted 
cDNA (1:10) was subjected to 45 cycles of quantitative 
PCR amplification using SYBR Green mix (SensiMix; 
Bioline) and 2 μM of each primer (Biolegio, Nijmegen, 
The Netherlands). A 2-step program was run on a 
LightCycler 480 (Roche Diagnostics). Melting curve 
analysis confirmed primer specificities. All reactions 
were run in duplicate and normalized to reference 
genes that showed stable expression in all samples: 
hydroxymethylbilane synthase (HMBS), hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and succinate 
dehydrogenase complex flavoprotein subunit A (SDHA). 
The PCR efficiency of each primer pair was calculated 
using a standard curve of reference cDNA. Amplification 
efficiency was determined using the formula 10-1/slope-1. 
The sequences of the used primer pairs are listed in 
Supplementary Table 1.
Multiplex analyses of pro-inflammatory 
cytokines/chemokines
Snap-frozen liver tissue was thawed in 1 mg/mL 
protease inhibitor cocktail (cOmplete, Mini, EDTA-free 
Figure 10: Preventive and therapeutic treatment of ASOs in experimental HCC. HCC was induced by weekly intraperitoneal 
DEN injection for 25 weeks. Control mice received weekly intraperitoneal 0.9% NaCl injection. DEN-treated mice were intraperitoneally 
injected with 20 mg/kg HIF-1α ASO, HIF-2α ASO or scrambled ASO twice per week. In the preventive setting, ASO injections started 
10 weeks following the first DEN injection (at 15 weeks of age) and persisted for a period of 15 weeks. In the therapeutic setting, ASO 
injections started 20 weeks following the first DEN injection (at 25 weeks of age) and persisted for a period of 8 weeks. Control mice 
received scrambled ASO for the same duration of the experiment. Following respective treatment periods, mice were sacrificed and the 
liver was isolated for further analyses.
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Protease Inhibitor Cocktail; Roche Diagnostics), 1 vol% 
phosphatase inhibitor cocktail 2 (Sigma-Aldrich) and 1 
vol% phosphatase inhibitor cocktail 3 (Sigma-Aldrich) 
in PBS, lysed by sonication and centrifuged (15 minutes, 
15,000 rpm, 4°C). The supernatant was stored at –80°C 
until further analysis. Total protein concentrations 
were measured using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to the manufacturer’s 
guidelines. Protein levels of TNFα, IL-6, IFN-γ, CCL2 
and CCL5 were determined by a bead-based Bio-Plex 
multiplex immunoassay (Bio-Rad Laboratories) according 
to the manufacturer's guidelines.
Histology
Liver samples were fixed in 4% phosphate-
buffered formaldehyde solution, dehydrated, embedded 
in paraffin, and sectioned (5 μm sections). Liver sections 
were stained with Sirius Red (Sigma-Aldrich). The extent 
of fibrosis was visualized using an Olympus BX41 
microscope (Olympus, Antwerp, Belgium) and Cell^D 
software (Olympus), and scored using the Metavir scoring 
system. The scoring was carried out by two independent 
researchers, who were blinded to the study samples.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6 (GraphPad Software, San Diego, California, USA). 
Normality was evaluated with the D’Agostino-Pearson 
omnibus test. Outliers were identified with the ROUT 
method, and excluded from the datasets. The maximum 
allowed false discovery rate was set to 1%. Normally 
distributed data were analyzed with the Student’s t-test or 
one-way analysis of variance (ANOVA) corrected with 
the Holm-Sidak test. Non-normally distributed data were 
analyzed using the Mann–Whitney U test or the Kruskal-
Wallis test corrected with Dunn’s multiple comparisons test. 
RT-qPCR data are expressed as log2-transformed mean ± SD 
relative to the log2-transformed mean of the control. Other 
measurements are expressed as median or mean ± SD. Two-
tailed p-values < 0.05 were considered statistically significant 
(*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001).
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